GO
Loading...

Merck & Co Inc

More

  • Asia shares mixed on lackluster China data Wednesday, 23 Apr 2014 | 12:06 AM ET

    TOKYO— Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector. Overnight, U.S. financial data and corporate earnings helped spur gains from deals by Switzerland's Novartis with Britain's GlaxoSmithKline PLC and the Eli Lilly& Co. of the U.S.

  • Pharma deals give stocks a lift Tuesday, 22 Apr 2014 | 5:22 AM ET

    HONG KONG— World stocks fluctuated Tuesday as a Wall Street rally powered by positive earnings reports offset investor cautiousness before a report on Chinese manufacturing and possible sanctions against Russia over Ukraine.

  • Valeant, Ackman make $45.6B Allergan bid Tuesday, 22 Apr 2014 | 12:03 AM ET

    NEW YORK— Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion. Each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant Pharmaceuticals International Inc. common stock.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • Valeant to bid for Botox maker Allergan Monday, 21 Apr 2014 | 5:40 PM ET

    NEW YORK— Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman to make a bid for Botox maker Allergan that could be worth about $40 billion. Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash.

  • AstraZeneca cancer pipeline seen as draw for Pfizer Monday, 21 Apr 2014 | 6:55 AM ET

    LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

  • FDA OKs Merck tablet to reduce ragweed allergies Thursday, 17 Apr 2014 | 3:56 PM ET

    WHITEHOUSE STATION, N.J.— U.S. regulators have again approved a Merck& Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen. The Food and Drug Administration approved it for patients aged 18 through 65.. Whitehouse Station, N.J.- based Merck's tablet for spring grass allergies, Grastek, was approved Monday for patients aged 5 to 65..

  • Merck's ragweed pollen allergy drug gets U.S. approval Thursday, 17 Apr 2014 | 3:00 PM ET

    April 17- The U.S. Food and Drug Administration has approved Merck& Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis.

  • Jobs outlook for Class of 2014 looks like this... Wednesday, 16 Apr 2014 | 1:14 PM ET

    Job prospects for this year's college graduates have changed a lot from last year, according to a new survey.

  • Smartphone apps remind patients to take their meds Wednesday, 16 Apr 2014 | 12:48 PM ET

    Medicine only helps if you take it properly. Still, only about half of patients take medication as prescribed, resulting in unnecessary hospital admissions and ER visits that cost the U.S. health care system an estimated $290 billion a year. Michael A. Weber, a cardiologist at SUNY Downstate Medical Center.

  • FDA OKs Merck tablet to reduce grass allergies Tuesday, 15 Apr 2014 | 3:15 PM ET

    WHITEHOUSE STATION, N.J.— Merck& Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old. Merck, based in Whitehouse Station, N.J., will market the tablet in North America. Its partner, ALK-Abello, sells it in Europe as Grazas.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • April 14- Merck& Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.

  • Biotechs in the green after last week's carnage Monday, 14 Apr 2014 | 2:58 PM ET

    Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.

  • LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • Midday movers: Netflix, Tesla Motors, CBS & More Thursday, 10 Apr 2014 | 12:45 PM ET

    Some of Thursday's midday movers:

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

  • U.S. stocks rose on Wednesday after Alcoa's quarterly profit topped expectations.

Most Popular Video

Thursday, 24 Apr 2014 | 8:49 AM ET

Today CNBC's Jim Cramer explains why he wishes his travel trust owned shares of Caterpillar, and shares his thoughts on the government's inability to create jobs.

Thursday, 24 Apr 2014 | 8:16 AM ET

Daniel Ernst, Hudson Square Research, provides perspective on Apple's earnings and growth potential. Apple is really innovating but they haven't done it in three years, Ernst says.

Thursday, 24 Apr 2014 | 8:02 AM ET

Doug Oberhelman, Caterpillar chairman & CEO, digs deep into the company's first quarter results and shares his outlook on global sales. CAT reported EPS of $1.44 on revenues of $13.24 billion, beating on both the top and bottom line.